View Older Stories View More Recent Stories

Jan 22, 2024 07:00AM Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema
Jan 8, 2024 08:00AM Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio
Jan 8, 2024 07:03AM Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases
Dec 22, 2023 04:00AM Ionis Pharmaceuticals (IONS) Announces FDA Approval of WAINUA
Dec 21, 2023 06:55PM WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis
Dec 20, 2023 07:05AM Ionis to present at 42nd Annual J.P. Morgan Healthcare Conference
Dec 18, 2023 04:01PM Ionis Pharmaceuticals (IONS) announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema
Dec 18, 2023 04:01PM Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema
Dec 14, 2023 04:07PM Ionis Pharmaceuticals (IONS) Appoints Michael Yang to its Board
Dec 14, 2023 04:05PM Ionis announces the appointment of Michael Yang to Board of Directors
Nov 16, 2023 08:00AM Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies
Nov 11, 2023 11:30AM Ionis shares positive clinical update from ongoing trial of ION582 for Angelman syndrome
Nov 9, 2023 12:43PM Ionis Pharmaceuticals (IONS) Present Positive Two-year Results from Phase 2 Study of donidalorsen
Nov 9, 2023 12:42PM Ionis presents positive two-year results from the Phase 2 open label extension study of donidalorsen in patients with hereditary angioedema
Nov 3, 2023 07:05AM Ionis to present at upcoming investor conferences
Nov 2, 2023 07:00AM Ionis reports third quarter 2023 financial results
Oct 19, 2023 07:05AM Ionis to hold third quarter 2023 financial results webcast
Oct 4, 2023 07:00AM Ionis shares significant business and pipeline progress at Innovation Day, highlighting strength of capabilities from research and technology through commercialization
Oct 2, 2023 01:17PM Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day
Sep 28, 2023 12:02PM Eplontersen Phase 3 results published in JAMA show consistent and sustained benefit
Sep 27, 2023 07:00AM Ionis Pharmaceuticals (IONS) enters agreement with Roche for two novel RNA-targeted programs for Alzheimer's disease and Huntington's disease
Sep 27, 2023 07:00AM Ionis enters agreement with Roche for two novel RNA-targeted programs for Alzheimer's disease and Huntington's disease
Sep 26, 2023 07:01AM Ionis Pharmaceuticals (IONS) Phase 3 study of olezarsen in people with familial chylomicronemia syndrome met its primary endpoint
Sep 26, 2023 07:00AM Ionis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndrome
Sep 12, 2023 07:05AM Ionis to host investor and analyst day event
Aug 30, 2023 07:05AM Ionis to present at upcoming investor conferences
Aug 9, 2023 07:00AM Ionis reports second quarter 2023 financial results
Aug 3, 2023 07:05AM Ionis enters collaboration to advance next generation program targeting Lp(a) for cardiovascular disease
Jul 31, 2023 07:05AM Ionis completes enrollment in landmark Phase 3 CARDIO-TTRansform study in patients with TTR-mediated amyloid cardiomyopathy
Jul 28, 2023 07:05AM Ionis Pharmaceuticals (IONS) Expands eplontersen Deal with AstraZeneca (AZN) to Include Latin America
Jul 28, 2023 07:05AM Ionis expands eplontersen agreement with AstraZeneca to include exclusive rights in Latin America
Jul 26, 2023 07:05AM Ionis to hold second quarter 2023 financial results webcast
Jul 10, 2023 07:05AM Ionis Pharmaceuticals (IONS) Reports Eplontersen Continued to Show Improvement in ATTRv-PN through 85 weeks
Jul 10, 2023 07:05AM Eplontersen continued to show improvement in ATTRv-PN through 85 weeks
Jul 5, 2023 07:05AM Ionis to present at upcoming investor conference
Jun 30, 2023 04:09PM Biogen (BIIB) Presents New Data on SPINRAZA
Jun 30, 2023 04:08PM New data highlight potential benefit of SPINRAZA® (nusinersen) in infants and toddlers with unmet medical needs after gene therapy
Jun 30, 2023 04:06PM New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy
Jun 1, 2023 07:10AM Ionis Pharmaceuticals (IONS) announces positive donidalorsen late-stage clinical progress in HAE
Jun 1, 2023 07:05AM Ionis announces positive donidalorsen late-stage clinical progress in HAE
May 10, 2023 07:05AM Ionis to host 2023 virtual Annual Meeting of Stockholders
May 9, 2023 07:05AM Ionis to present at upcoming investor conferences
Apr 26, 2023 05:41AM Ionis Pharmaceuticals (IONS) Announces FDA Approval of QALSODY
Apr 25, 2023 07:10PM FDA approves QALSODY™ (tofersen) as the first treatment targeting a genetic cause of ALS
Apr 24, 2023 07:01AM Ionis Pharmaceuticals (IONS) says Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study through 66 weeks
Apr 24, 2023 07:00AM Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study through 66 weeks
Apr 20, 2023 07:05AM Ionis to hold first quarter 2023 financial results webcast
Mar 29, 2023 08:45AM New data presented at AD/PD™2023 show IONIS-MAPT Rx (BIIB080) substantially reduced tau protein in patients with early-stage Alzheimer's disease
Mar 28, 2023 07:05AM Ionis to present at upcoming investor conferences
Mar 27, 2023 05:49AM Ionis Pharmaceuticals (IONS) Reports Positive 66-week Phase 3 Data for eplontersen
View More Recent Stories View Older Stories